Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YL 201

Next Previous
Drug Profile

YL 201

Alternative Names: YL-201

Latest Information Update: 06 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MediLink Therapeutics
  • Developer Amgen; MediLink Therapeutics
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Squamous cell cancer; Small cell lung cancer; Nasopharyngeal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Nasopharyngeal cancer; Small cell lung cancer
  • Phase II Prostate cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 31 Mar 2026 MediLink Therapeutics plans a phase I/II trial for Solid tumours (Late-stage disease, First-line therapy) in the US, Germany, Italy, Hungary, Belgium, France, Poland, Romania and Spain (IV) (NCT07407933) (CTIS2025-523742-27-00)
  • 23 Mar 2026 MediLink Therapeutics plans the phase III TAISHAN-303 Oesophageal cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease, Monotherapy) in China in April 2026 (IV, Infusion) (NCT07487896)
  • 12 Feb 2026 MediLink Therapeutics plans a phase II trial for Small cell lung cancer (Combination therapy, Late-stage disease, First-line therapy) in USA in March 2026 (IV) (NCT07407933)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top